Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.

Exclusion Criteria

• •1. Have clinically significant disease that hepatobiliary system(severe hepatic impairment, etc), kidney(severe renal impairment, etc.), nervous system, immune system, respiratory system, endocrine system,hemato-oncology disease, cardiovascular system (heart failure, etc.).or mental illness, or a history of mental disease.
• •2. Have a gastrointestinal disease history that can affect drug absorption (Crohn, ulcers, etc.) or surgery (except simple appendectomy or hernia surgery)
• •3. Hypersensitivity reaction to drug or clinically significant hypersensitivity reaction in the history of Investigational drugs (telmisartan, s-amlodipine or atorvastatin calcium) or additives
• •4. An impossible one who participates in clinical trial including screening tests(medical history taking, BP, physical examination, 12-lead ECG, blood \& urine laboratory test result) within 28 days before the beginning of study treatment.
• •5. Defined by the following laboratory parameters:
• •* AST, ALT\> 1.25\*upper limit of normal range
• •* Total bilirubin \> 1.5\* upper limit of normal range
• •* CPK \> 1.5\* upper limit of normal range
• •* eGFR(using by MDRD method) \< 60 mL/min/1.73m2
• •6. Sitting SBP \> 150 mmHg or \< 90 mmHg, Sitting DBP\> 100 mmHg or \< 50 mmHg , after 5minuts break.
• •7. Drug abuse or have a history of drug abuse showed a positive for the Triage TOX drug on urine.
• •8. Pregnant or lactating women.
• •9. A heavy caffeine consumer(caffeine\>5cups/day), alcohol consumer(alcohol\>210g/week), or smoker(cigarette\>10cigarettes /day)
• •10. Subject takes ethical drug or herbal medicine within 14days, OTC within 7days before the beginning of study treatment but investigator determine that the taking drug affect this study or could affect the safety of the subjects.
• •11. Subject who takes inhibitors and inducers of drug metabolizing enzyme(Barbiturates etc.) within 30 days.
• •12. Taking foods containing grapefruit within 7 days before the beginning of study treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days before the beginning of study treatment)
• •13. Subject who treated with any investigational drugs within 60days before the beginning of study treatment (However, biologicals applies for 90 days, but can be based on a more extended period of time by considering the half-life.
• •14. Previously donate whole blood within 60 days or component blood within 30days.
• •15. An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
• •16. Positive for Hepatitis B, Hepatitis C, HIV